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Introduction
Cryopyrin associated periodic syndromes (CAPS) are
caused by autosomal dominant gain of function mutations
in the NLRP3 gene. However, up to 50% of clinically diag-
nosed CAPS patients with typical clinical features and
good response to anti-IL-1b treatment have no mutation
detected by conventional Sanger DNA sequencing. Recent
studies suggest that somatic NLRP3 mosaicism may
account for a proportion of these apparently “mutation-
negative” patients. Another possible explanation is that
CAPS can be caused by other genetic mutations.
Objectives
The aim of this study was therefore to assess the relative
contributions of NLRP3 somatic mosaicism or alternative
genetic cause in a cohort of paediatric and adult patients
with a clinical diagnosis of CAPS, but who were NLRP3
mutation negative by Sanger sequencing.
Methods
To detect somatic mosaicism for NLRP3 we performed
massively parallel sequencing (MPS) of NLRP3 with high
coverage of DNA extracted from peripheral blood. In the
patients who were negative for somatic mosaicism using
MPS, we then went on to perform Whole Exome
Sequencing (WES) on DNA from peripheral blood from
select cases using the Illumina TruSeq or Nextera Exome
capture and HiSeq sequencing platforms. Exome data
was analysed in the Galaxy web-based suit.
Results
Eight patients including 4 children (n=2 with CINCA;
n=2 with Muckle-Wells syndrome [MWS]; and 4 adults
with late-onset MWS) were studied. MPS analyses
revealed a variable degree of somatic NLRP3 mosaicism
in 6/8 (75%) patients: 4 adults and 2 children. Two
patients with MWS carried the previously described
pathogenic p.E567K NLRP3 mutation in 3.1% and 5.6%
of alleles respectively; one of the CINCA patients had
the pathogenic p.F556L NLRP3 mutation in 14.5% of
alleles; the other two unrelated adult patients had a novel
p.Y563C NLRP3 mutation in 7.3% and 9.75% of alleles
respectively. The last adult patient had the pathogenic
p.A352T mutation, previously described as a pathological
germline mutation, at an allele frequency of 16.1%.
WES was performed in the remaining 2 patients (n=1
CINCA; n=1 MWS). WES revealed a novel NOD2
mutation in the CINCA-like patient, which was con-
firmed by Sanger sequencing and segregated with the
disease in family studies, thus confirming the diagnosis
of Blau’s syndrome rather than CINCA; in the other
patient a definite causal mutation is yet to be found
using WES.
Conclusion
Somatic NLRP3 mosaicism accounted for 75% of the
“NLRP3 mutation-negative” cases in this cohort which
confirms the importance of genetic somatic mutation in
the aetiopathogenesis of CAPS. This included 4 adults
with adult-onset disease, making this the first descrip-
tion of low-level somatic NLRP3 mosaicism as a cause
of late-onset MWS in adulthood. WES revealed a novel
NOD2 mutation in one child with atypical CINCA,
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emphasizing that there may be a significant clinical
overlap between different auto-inflammatory syndromes;
for the remaining case of MWS, WES has yet to reveal
the genetic cause, and therefore whole-genome sequen-
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